Results 41 to 50 of about 870 (107)

A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary Tuberculosis. [PDF]

Clin Infect Dis
de Jager V, Mockeliunas L, You H, Simonsson USH, Collings T, Upton CM, Bezuidenhout JA, Gupte N, Dorman SE, Nuermberger E, Lamichhane G, Diacon AH, Dooley KE.   +12 more
europepmc   +1 more source

New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Lung Transplantation: Clinical Evidence, Safety, and PK/PD Properties. [PDF]

Transpl Int
Lombardi A, Mangioni D, Viero G, Alagna L, Renisi G, Saltini P, Bandera A.   +6 more
europepmc   +1 more source

Molecular and pharmacodynamic insights into β-lactam therapy for high-inoculum <i>Enterobacter cloacae</i> complex infections. [PDF]

Antimicrob Agents Chemother
Kunz Coyne AJ, Gray R, May E, Curry H, Slain N, Delcher C, Shin E.   +6 more
europepmc   +1 more source

Potential interactions between vancomycin and meropenem in culture-negative periprosthetic joint infection: an in vitro study. [PDF]

BMC Microbiol
Yao L, Ma Y, Liu R, Li Y, Sun X, Wahafu T, Cao L, Mu W.   +7 more
europepmc   +1 more source

Comparison of 2-hour drip infusions of meropenem versus piperacillin/tazobactam for febrile neutropenia in pediatric patients. [PDF]

Antimicrob Agents Chemother
Kobayashi R, Sano H, Ishigaki R, Matsushima S, Hori D, Yanagi M, Suzuki D.   +6 more
europepmc   +1 more source

Comparative effectiveness of two antimicrobial regimens for the treatment of pan-drug-resistant <i>Acinetobacter baumannii</i> infections: results from the DESPAIR study. [PDF]

Antimicrob Agents Chemother
Pontikis K, Karaiskos I, Sakagianni A, Mouloudi E, Tsigou E, Gkoufa A, Michelidou S, Mouratidou K, Gavala A, Routsi C, Karakonstantis S, Michalea S, Ampelioti S, Katsarou T, Papathanasiou A, Pirounaki M, Anastogiannis C, Koutsoukou A, Giamarellou H, Daikos GL, DESPAIR Study Group.   +20 more
europepmc   +1 more source

Simultaneous measurement of piperacillin, tazobactam and meropenem in patient samples using LC-MS/MS to support β-lactam therapeutic drug monitoring.

Anal Methods
Federico S, Williams S, Wilson RC, Arkel P, Gilchrist MJ, Holmes AH, Rawson TM, Riezk A.   +7 more
europepmc   +1 more source

Disarming carbapenemase-producing <i>Acinetobacter baumannii</i>: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310). [PDF]

Antimicrob Agents Chemother
Rodríguez-Pallares S, Outeda-García M, Lence E, Rodríguez-Coello A, González-Pinto L, Guijarro-Sánchez P, Báez-Barroso GA, Blanco-Martín T, Vázquez-Ucha JC, Llanos A, Sannio F, Docquier J-D, Morrisey I, Hawser S, Zalacain M, Lemonnier M, González-Bello C, Bou G, Beceiro A, Arca-Suárez J.   +19 more
europepmc   +1 more source

Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model. [PDF]

J Antimicrob Chemother
Fratoni AJ, Padgett AM, Duffy EM, Nicolau DP.   +3 more
europepmc   +1 more source

Characterization of bacteriophages PAA and PAM and evaluation of their antibiotic synergy against Pseudomonas aeruginosa PAZMYU isolated from urine sample. [PDF]

BMC Microbiol
Nawaz A, Khalid NA, Majid A, Shahzadi M, Zafar S, Khan MI, Khan N, Khalid A, Shah AA, Badshah M, Khan S.   +10 more
europepmc   +1 more source